{
  "ticker": "FULC",
  "company_name": "Fulcrum Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04511819",
      "title": "Losmapimod Safety and Efficacy in COVID-19",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "COVID-19",
      "start_date": "2020-08-28",
      "completion_date": "2021-03-31",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT04003974",
      "title": "Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "start_date": "2019-08-09",
      "completion_date": "2021-01-28",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT05169580",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Sickle Cell Disease, Sickle Cell Anemia",
      "start_date": "2021-12-13",
      "completion_date": "2026-01",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT04004000",
      "title": "Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Facioscapulohumeral Muscular Dystrophy 1",
      "start_date": "2019-08-23",
      "completion_date": "2024-10-31",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT05397470",
      "title": "Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "start_date": "2022-06-16",
      "completion_date": "2024-11-19",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT04264442",
      "title": "Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "start_date": "2020-02-13",
      "completion_date": "2024-11-07",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT05002231",
      "title": "Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Adult Subjects",
      "start_date": "2021-08-19",
      "completion_date": "2021-10-22",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    },
    {
      "nct_id": "NCT04586985",
      "title": "Safety, Tolerability and Pharmacokinetics of FTX-6058",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Adult Subjects, Sickle Cell Disease",
      "start_date": "2020-10-26",
      "completion_date": "2022-11-15",
      "enrollment": 0,
      "sponsor": "Fulcrum Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 8,
    "by_phase": {
      "PHASE3": 2,
      "PHASE2": 3,
      "PHASE1": 3
    },
    "by_status": {
      "TERMINATED": 4,
      "COMPLETED": 3,
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 3,
    "conditions": [
      "COVID-19",
      "Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "Facioscapulohumeral Muscular Dystrophy 1",
      "Healthy Adult Subjects",
      "Healthy Adult Subjects, Sickle Cell Disease",
      "Sickle Cell Disease, Sickle Cell Anemia"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:31.179835",
    "search_query": "Fulcrum Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Fulcrum+Therapeutics,+Inc."
  }
}